Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT01329068
What this trial is testing

Patient Empowerment by Group Medical Consultations

Who this might be right for
Breast CancerBRCA Mutation
Radboud University Medical Center 320
Testing effectiveness (Phase 2)Enrolling By InvitationNCT07743268
What this trial is testing

Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS

Who this might be right for
Amyotrophic Lateral Sclerosis (ALS)
n-Lorem Foundation 6
Testing effectiveness (Phase 2)UnknownNCT00299897
What this trial is testing

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

Who this might be right for
HIV InfectionsHuman Immunodeficiency Virus
Samaritan Pharmaceuticals, Inc 60
Testing effectiveness (Phase 2)UnknownNCT03647956
What this trial is testing

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Activating Mutation
The University of Hong Kong 40
Testing effectiveness (Phase 2)Study completedNCT00586651
What this trial is testing

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Who this might be right for
Polycythemia VeraEssential Thrombocytosis
Cephalon 39
Large-scale testing (Phase 3)Study completedNCT04185363
What this trial is testing

An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Who this might be right for
Progressive Familial Intrahepatic Cholestasis (PFIC)
Mirum Pharmaceuticals, Inc. 84
Testing effectiveness (Phase 2)Ended earlyNCT04933695
What this trial is testing

Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

Who this might be right for
Non-small Cell Lung Cancer
Amgen 42
Early research (Phase 1)UnknownNCT03645200
What this trial is testing

Treatment of Carrying TP53 Harmful Mutations

Who this might be right for
Advanced Cancer
Tianjin Medical University Second Hospital 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05751187
What this trial is testing

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Who this might be right for
Non-squamous NSCLC
Shanghai Chest Hospital 54
Testing effectiveness (Phase 2)UnknownNCT05102292
What this trial is testing

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Who this might be right for
Anaplastic Thyroid CancerATC
Shanghai Henlius Biotech 25
Large-scale testing (Phase 3)Active Not RecruitingNCT04143607
What this trial is testing

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 337
Testing effectiveness (Phase 2)UnknownNCT05016544
What this trial is testing

Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 48
Testing effectiveness (Phase 2)Looking for participantsNCT05983237
What this trial is testing

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

Who this might be right for
Melanoma
Jun Guo 50
Early research (Phase 1)Study completedNCT01225536
What this trial is testing

Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations

Who this might be right for
Solid Tumor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 24
Large-scale testing (Phase 3)Study completedNCT02756611
What this trial is testing

Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Chronic Lymphocytic Leukemia
AbbVie 258
Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Testing effectiveness (Phase 2)Study completedNCT00588445
What this trial is testing

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Who this might be right for
Lung CancerNon-small Cell Lung CancerBronchioloalveolar Cancer
Memorial Sloan Kettering Cancer Center 65
Testing effectiveness (Phase 2)Study completedNCT02927301
What this trial is testing

Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

Who this might be right for
Non-Small Cell Lung Cancer
Genentech, Inc. 181
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Large-scale testing (Phase 3)Active Not RecruitingNCT06780930
What this trial is testing

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Who this might be right for
Residual or Recurrent Grade 2 IDH Mutant Glioma
Servier 57
Next Page